
Gene therapy halts progression of rare genetic condition
The findings from a single-patient gene therapy trial in Canada show promise in halting the progression of spastic paraplegia type 50 (SPG50). SPG50 is an ultra-rare progressive neurodegenerative disorder that causes developmental delays, speech impairment, seizures, progressive paralysis of all four limbs, and is typically fatal… Read More













